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Abstract
The Novartis Institutes for BioMedical Research is the drug discovery arm of Novartis
Pharmaceuticals. Drug discovery is generally considered to be the primary driver for success in the
pharmaceutical industry. Success in the early stages of drug discovery relies on dependable, innovative,
disease related high-throughput screening of biological compounds and the creation of a screening deck
of highly diverse, proprietary chemical compounds. In contrast with many of its peers, Novartis relies
strongly on combinatorial chemistry to populate its screening deck. The Chemical Libraries (CLI) group
is responsible for this approach at Novartis and delivers more than 100,000 compounds per year to the
Novartis Compound Archive. Since the introduction of high-throughput screening and combinatorial
chemistry techniques, the bottleneck in many drug discovery processes has shifted to the roles that
support these high-volume techniques.
The aim of this thesis is to provide a general collection of short and long-term suggestions for
process improvement in the chemical supply process. This process includes compound search and
ordering, order fulfillment, and compound delivery, was investigated. The chemical supply process is
responsible for delivering compounds to chemists that would otherwise cost hundreds of dollars per
compound with a delay of between one and four weeks, or would require a multiple day synthesis
procedure. Stockroom automation, content and process scope, and physical layout were all evaluated.
The following major conclusions were developed as a result of the research. First, the procedures
for using the compound archives and libraries must be clearly presented to the end user so that s/he is
fully able to utilize and contribute to the libraries. Second, compound libraries should be conglomerated
into one large library that is also responsible for compound acquisition. Third, compound metering for
intermediates does not appear to be an effective use of resources and should be severely restricted
following the successful implementation of the SciQuest compound management system. Finally,
compound libraries should use automated pick and place systems but metering and dispensing systems
should remain manual.
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1 Introduction
1.1 Project Motivation
The pharmaceutical industry has entered a more competitive era with higher costs of drug
discovery and fewer "blockbuster" drugs. This new environment dictates the need for a more efficient
and streamlined discovery process. Efforts to automate and institute high-throughput discovery
techniques have pushed the bottleneck in the discovery pipeline upstream, so that it now often resides in
supporting resources for these techniques.
Upstream processes are now generally regarded as inhibiting bottlenecks in many drug discovery
organizations. Consequently, it is now a high priority to maximize the efficiency of synthetic chemistry
processes. A large factor in the ability of chemists to efficiently produce desired compounds is the
availability of chemical intermediates or building blocks, chemical precursor compounds that are used in
the synthesis of drug candidate compounds. Better availability of commercially available and proprietary
compounds will have a direct impact on chemists' efficiency.
This thesis takes a broad look at the system for supplying intermediate and building block
compounds to the chemists and attempts to discern a configuration that maximizes responsiveness,
accessibility and quality of compounds, while minimizing costs. The libraries that hold these building
blocks are an essential component of the synthetic chemistry process. Each archive contains 20 - 30
thousand compounds. Many of these compounds are proprietary and would take, on average,
approximately two days of a technician's time to prepare from scratch. The compounds that are
commercially available cost hundreds of dollars per order and have lead times from several days to a
month. Consequently, optimal functionality of compound libraries saves Novartis thousands of dollars
per day and, more importantly, dramatically decreases cycle time for compound production.
1.2 Thesis Overview
This document is organized as described below:
Chapter 1 outlines the general motivation for this project and gives an overview of the thesis.
Chapter 2 provides a brief discussion of Novartis and the Novartis Institutes for BioMedical Research. It
also delivers a concise outline of the industry and competitors.
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Chapter 3 discusses the evolution and current state of the drug discovery process with special emphasis
on medicinal chemistry. This chapter aims to supply an initial understanding of the needs of the customer
and the materials properties that are typically desired by the customer.
Chapter 4 introduces the project by discussing the setting and goals of the problem along with the
approach that was implemented.
Chapter 5 details the current service offerings that are available, gives a brief overview of the customer
locations, and discusses utilization.
Chapter 6 investigates the customer definition of value, customer satisfaction and desires, current
ordering procedures, archive workflow and content, and competitor approaches.
Chapter 7 explores the use of automation in the specific archives and discusses the options that are
currently on the market.
Chapter 8 describes a suggested future archive, to be implemented as part of the Novartis Campus
Project, that implements many of the improvements discussed earlier in the paper.
Chapter 9 summarizes the findings from the research.
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2 Industry and Company Background
2.1 Industry Summary
The pharmaceutical industry is highly consolidated with large barriers to entry. The top 10
companies made up almost 50% of sales in 2005. Research and development costs for new compounds
are generally extremely high; in 2005, the biopharmaceutical industry spent an estimated USD 51.3
billion on research and development costs'. Approval from the Food and Drug Administration (FDA) for
a new drug application (NDA) is also an arduous and costly process. Additionally, only one in 5000
compounds makes it to market and only one third of commercial drugs are successful enough to
recuperate their own research and development costs. This environment favors large companies that are
able to spread risk among many drug candidates. The 10 largest pharmaceutical companies and their
2005 sales are listed in Table 1.
I-i1Zt•r
GlaxoSmithKline
Sanofi-Aventis
Novartis
Johnson & Johnson
AstraZenica
Merck
Roche
Abbott Labs
Wyeth
[+/.O
34.7
30.0
28.5
25.3
24.1
23.5
19.8
15.7
14.7
Table 1 - Leading pharmaceutical companies in 2005 (pharmaceutical sales only)2
As noted above, most drug candidates end up being unsuccessful and many of the ones that do
make it to market cannot produce enough revenue to justify their costs. On average, it requires about
' Source: Pharmaceuical Research and Manufacturers of America. "Pharmaceutical Industry Profile 2006."
Washington, DC: PhRMA, March 2006.
2 Source: Saftlas, Herman., et. Al. "Healthcare: Pharmaceuticals." Standard & Poor's Industry Surveys. May 25,
2006.
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yeth
......
USD 800 million and ten to fifteen years to develop a new drug3. This leads pharmaceutical
manufactures to focus on what are deemed "blockbuster" drugs, compounds that generate more than USD
1 billion for their owner4. It is hoped that these "blockbusters" will produce enough revenue to cover the
costs of their development as well as the costs of all the failed candidates. The ten leading drugs by sales
in the United States are listed in Table 2, below.
Lipitor (Pfizer) Cholesterol reducer
Zocor (Merck) Cholesterol reducer
Nexium (AstraZenica) Antiulcer
Prevacid (TAP Pharma-Abbott) Antiulcer
Advair Diskus (GlaxoSmithKline) Antiasthmatic
Plavix (Sanofi Pharmaceuticals) Blood clot inhibitor
Zoloft (Pfizer) Antidepressant
Epogen (Amgen) Red blood cell stimulant
Procrit (Johnson & Johnson) Antianemia
Aranesp (Amgen) Antianemia
8.4
4.4
4.4
3.8
3.6
3.5
3.1
3.0
3.0
2.8
Table 2 - Leading US drug sales in 2005"
Once a company has successfully developed a novel compound, its research and development
investment is protected under patent law. A patent is a legal barrier to entry that prohibits competitors
from entering the market for a compound. Patents can be issued based on the drug's chemical structure or
on its method of manufacture. The World Trade Organization (WTO) requires all of its member
countries to recognize patents and grants protection for 20 years following the date of application.
Because it takes a significant amount of time to bring a product from the application stage to the market,
the effective length of protection in the market is effectively only eight to 10 years".
A drug that has lost its patent protection can be produced by any manufacturer as a generic drug.
Additionally, manufacturers can submit their drug in the United States for faster FDA approval under an
3 Source: Pharmaceuical Research and Manufacturers of America. "Pharmaceutical Industry Profile 2006."
Washington, DC: PhRMA, March 2006.
4 Generally, blockbuster drugs address afflictions that have large populations of victims. However, this is not a
necessary criterion, as notably illustrated by drugs that treat Orphan Diseases, such as Genzyme's Cerezyme (2006
revenues USD I billion, with significantly less than 10,000 patients).
5 Source: Saftlas, Herman., et. Al. "Healthcare: Pharmaceuticals." Standard & Poor's Industry Surveys. May 25,
2006.
6 Ibid.
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expedited abbreviated new drug application (aNDA). Once a drug is in the generic stage, more
competitors enter the market and generally erode the profitability of the innovator. The strategy in this
more competitive market is somewhat different; manufacturers tend to compete on cost rather than on
perceived quality.
Generic drugs are taking on added significance in the contemporary market. In 2006 alone, drugs
with a combined USD 21.3 billion market share will lose patent protection. Between 2006 and 2010, 70
or more drugs will lose patent protection. At least 19 of these are considered "blockbuster" drugs. This
places additional pressure on those responsible for drug discovery to produce new compounds to replace
them.7
Many companies are also trying to fight the onslaught of generic competition by forging
agreements with generics manufacturers to produce "authorized generics" slightly before patent
expiration. This gives the selected generic manufacturer an advantage but discourages additional
competition. Other manufacturers, such as Novartis, have decided to produce generics in-house,
generally within a separate division. This reduces the required legal and marketing budget that would be
squandered defending the labeled drug while allowing the company to maintain market share in the
generic drug, which will generally have a leg up on the competition.
Global pharmaceutical sales are still growing faster than the economy in general, but there is
expected to be a marked deceleration of growth. The United States is, by far, the largest segment of the
market, with 2005 sales of U1SD 252.2 billions . Figure 1 below shows the global division of sales.
' Ibid.
8 Ibid.
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Figure 1 - 2005 Pharmaceutical sales by region in Billion USD 9
2.2 Novartis AG
Novartis resides in Basel, Switzerland and was formed on March 7, 1996 by the merger of
Sandoz and Ciba-Geigy. At the time, this was the largest corporate merger in history. At year-end 2005,
Novartis net sales of USD 32,212 MM, providing a 21.4% Return on Sales 0". The present incarnation of
Novartis is a result of a long history of corporate mergers and acquisitions.
Novartis is divided into three divisions, with a fourth pending shareholder approval. Sales for the
three pre-existing divisions for calendar year 2005 was USD 20,262M, divided by division as illustrated
in Figure 2.
9 Ibid.
o0 Source: Novartis Annual Report 2005 < http://www.novartis.com/downloads/2005 annualresults_E.pdf>
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Figure 2 - Novartis sales by division for 2005
The Novartis Pharmaceuticals division is responsible for general and specialty medicines to treat
a large range of conditions. The top ten selling Novartis pharmaceuticals for 2005 are listed in Table 3.
In recent years the Novartis pipeline has been more successful than the industry average. Novartis
contributes a large part of this success to it's unique drug discovery unit's organization and methods.
ulovan
Zometa
Lamisil Group
Lotrel
Neoral/Sandimmun
Sandostatin/LAR
Lescol Group
Voltaren
Trileptal
1,521
524
704
538
-.. -- .-- I
1,075
150
376
257
5
462
1,646 I
1,646
520
595
0
803
520
510
684
153
Table 3 - Top 10
1,o0/0
1,224
1,133
1,075
953
896
767
689
615
1
1
1
3
1
8
3
7
nypertension
Chronic Myeloid Leukemia and Gastrointestinal
Stromal Tumors
bone metastasis and a variety of tumors
antifungal agent
hypertension
immunosupressive agent for transplantations
reduce blood levels of growth hormone and IGF-I
in acromegaly patients
atherosclerosis
Nonsteroidalanti-inflammatory, antirheumatic
agent
epilipsy
Novartis pharmaceutical compounds for 2005"
Following the acquisitions of Hexal and Ion Labs, the Sandoz division is the world's second
largest supplier of generic pharmaceuticals. Novartis is the only company that can claim a position as one
" Ibid.
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Glivec 2,170
· _ , , ~
of the top five producers of both branded and generic drugs' 2. Sandoz has an entirely separate supply
chain from the Pharmaceuticals division and is generally viewed internally as competition. However,
Novartis is actively working to institute a process of allowing Sandoz early access to Novartis patents
setting the groundwork for early launch to gain larger amounts of generic market share. It is hoped that as
a result of this handoff, the loss to the Pharmaceuticals division due to cannibalism will be more than
accounted for by the increased sales in generics and the reduced marketing and legal expenses of
protecting the name brand drug.
The Novartis Consumer Health division produces Over the Counter drugs, animal health
products, Gerber baby products, and CIBA vision products. Similar to Sandoz, OTC drug sales can gain
a synergistic advantage with the Pharmaceuticals division by working to reformulate prescription drugs
and brand names into OTC dosages as patents expire. In December 2006, Novartis sold its medical
nutrition products group to Nestle SA, for USD 2.2 billion, in an attempt to focus more on
pharmaceuticals1 3.
The new Vaccines and Diagnostics division will consist of the Chiron Corporation's diagnostics
and vaccines businesses. It is the world's fifth-largest vaccine maker and the second-largest manufacturer
of flu vaccines. 14 The Vaccines and Diagnostics division is headquartered in Emeryville, CA.
2.3 Novartis Institutes for BioMedical Research (NIBR)
The Novartis Institutes for BioMedical Research (NIBR), organized in May 2002, is the global
research organization of Novartis. NIBR currently has seven locations, illustrated in Figure 3, with an
eighth USD 100 Million facility slated for construction in July 2007 in China' 5. The world headquarters
is located in the Cambridge, MA location but the largest facility is located in Basel, Switzerland with
approximately 1600 employees.
12 Source: Whalen, Jeanne. "Betting $10 Billion on Generics, Novartis Seeks to Inject Growth." The Wall Street
Journal. A1, May 4, 2006.
13 Source: Ball, Deborah and Jeanne Whalen. "Nestl6 Buys Novartis Nutrition Unit." The Wall Street Journal. A10,
December 15, 2006.
14 Source: <http://www.novartisvaccines.com/>
15 Source: Zamiska, Nicholas. "Novartis to Establish Drug R&D Center in China." The Wall Street Journal. A3,
November 6, 2006.
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NIBR is sub-divided into ten Disease Areas' 6, which focus on major areas of human affliction.
Additionally, NIBR contains eight Expertise Platforms'7 , which work in parallel to the Disease Areas and
provide understanding of particular research technologies.
Figure 3 - NIBR Locations"8
Following is a brief description of drug discovery methodology that is typical of the Novartis
approach for small molecule drugs with a specific focus on the US market. The approach for other
pharmaceutical companies and, to a lesser extent, biotechnology firms is similar.
16 The ten Disease Areas are Autoimmunity & Transplantation, Cardiovascular, Diabetes & Metabolism,
Gastrointestinal, Ophthalmology, Infectious Diseases, Musculoskeletal, Neuroscience, Respiratory Diseases, and
Oncology
~7 The eight Expertise Platforms are the NIBR Biologics Center, Developmental & Molecular Pathways, Discovery
Technologies, Center for Proteomic Chemistry, Epigenetics, Genome & Proteome Sciences, Global Discovery
Chemistry, and Models of Disease
" Source: NIBR Web site <http://nibr.novartis.com/Downloads/About/NIBR printablemap.pdf>
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3 The Process of Drug Discovery
3.1 Introduction
For millennia, man has harnessed the medicinal properties of naturally occurring drugs, initially
utilizing plant sources. The practice of analytical chemistry became relevant to medicine in the 19th
century when, in 1815 Serttirner was able to isolate morphine from opiumr• ' . In 1938, Chain and Florey
made the fortunate decision to further study Fleming's penicillin. The immense success of penicillin
provided an impetus for general research on antibiotics19. The 1950's saw the beginning of isolating
natural products used as leads and random screening in animals. This early mechanism of drug discovery
was a serial process in which the isolated natural compounds were then sent off to be tested in simple
biological screens and rodents. The results of the screens were then used to chemically modify the
compound and the feedback loop was repeated until a satisfactory result was produced. The next steps
were animal testing and clinical trials, followed by FDA approval and production.
At this early stage, the animal testing process was the primary bottleneck in the discovery
pipeline. However, in the 1970's molecular modeling and in vitro experimentation became available to
filter compounds. This allowed for more intelligent and selective animal testing and shifted the
bottleneck to the lead-optimization stage. Then, in the 1980's computer aided modeling and structure-
based design tools, such as NMR were added to the drug discovery toolbox, further refining the number
and quality of compounds escaping the discovery process. 20
The lead-optimization bottleneck in the pipeline prohibited the pharmaceutical industry from
developing new drugs at a pace that satisfied corporate investors. Following the introduction of high-
throughput screening (HTS) between 1989 - 1991, companies achieved the ability to screen millions of
compounds in high-capacity biological assays, thus pushing the bottleneck from screening to medicinal
chemistry21 and in silico drug design.
Focus on eliminating the new constraints, led to the development of the techniques of
combinatorial chemistry and parallel chemistry. Success of these techniques requires several significant
supporting resources including insightful design, automation and robotics, and, notably for this thesis, a
diverse, unique and readily available supply of precursors.
19 Source: Drews, J. "Drug discovery: A historical perspective." Science. 287, 2000, 1960 1964.
20 Much of the general information for this section is taken from Ali, Mohammad Farat et. Al. Handbook of
Industrial Chemistry: Organic Chemicals. New York: McGraw-Hill, 2005, 337-347.
21 Source: Edwards, Paul J. "The Impact of Parallel Chemistry in Drug Discovery." !I)rugs. 9, 2006, 347-353.
Page 20 of 87
Of course, in addition to focusing on the throughput rate of the drug development pipeline, it is
equally important to focus on the quality of the product from each step in the process. The early efforts of
combinatorial chemistry were more like a "shotgun approach" designed to maximize primarily the
quantity of compounds produced, yielding large but generally low quality libraries. This initial foray led
to the conclusion that the two primary indicators of success are quality and diversity. The former refers to
both purity of the compounds and the defensibility of their intellectual property. It is improved by more
efficient purification techniques and the use of more novel, proprietary intermediate sources. The latter is
a result of scaffold and building block selection, which is limited by the available supply to the chemists.
Many pharmaceutical manufacturers became frustrated with the lack of return on combinatorial
drug design methods and abandoned the concept almost entirely. However, others, including Novartis,
began an emphasis on parallel synthesis, a derivative of combinatorial chemistry that addresses the
problems discussed above. Parallel synthesis is thought to add value in all stages of drug development
form hit finding to lead optimization.
Parallel synthesis relies highly on a readily available, high quality selection of proprietary and
commercial compounds. The focus of this thesis is to evaluate the functionality of the reagent and
chemical intermediate supply and storage for chemical synthesis, in order to enable a faster and more
effective collection, distribution and storage of commercial and proprietary building blocks and reagents.
Currently, about I out of 10,000 compounds that are prepared in the optimization process
eventually becomes a new drug. Better filtering in the early stages of development helps to alleviate
exponentially greater per compound costs at the later stage, leaving resources for focusing on the truly
promising leads. However, Research and Development expenditures for BioPharmaceutical companies
reached an estimated USD 51.3 Billion in 200522. Figure 4 illustrates growing cost of Research and
Development as a function of sales. 'The research and development path is illustrated generally in Figure
6 and more specifically for Novartis in Figure 5. It typically takes 10 - 15 years to go from initial
discovery to FDA approval 23.
22 Source: Pharmaceutical Research and Manufacturers of America. Pharmaceutical Industry Profile 2006
Washington, DC: PhRMA, 2006, 47.
23 Ibid.
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Figure 4 - R&D costs for PhRMA Member Companies 24
Figure 5 - Drug Discovery and Development process at Novartis25
24 Ibid.
25 Source: Novartis NIBR web site < http://nibr.novartis.com/OurScience/drug discovery.shtml>
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Figure 6 - The journey from hit to drug26
3.2 Target Selection
The first step on the path of the classical, bottom-up approach to drug discovery and development
is target identification and selection. A target is generally described as a therapeutic area for an affliction
that currently does not have a satisfactory remedy. The four types of targets for small molecule
therapeutic agents are proteins, polysaccharides, lipids and nucleic acids. Figure 7 depicts the most
common targets for small molecule orally administered drugs. The most common target, an enzyme, is a
protein that acts as a highly specific catalyst in cell metabolism. More recently pharmaceutical companies
26 Source: Pharmaceutical Research and Manufacturers of America. Pharmaceutical Industry Profile 2006.
Washington, DC: PhRMA, 2006, 47.
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have begun to target kinases. Novartis has done groundbreaking work in this field, culminating in the
discovery of Gleevec. The second most common target, G-protein coupled receptors (GPCRs), sit on the
cell wall and allow information from outside the cell to be transported into the cell. Typically, a ligand
attaches to the receptor cite external to the cell, causing a change in physical conformation of the GPCR.
This leads to a release of a G-protein on the inside of the cell. Most drugs that target GPCRs act to either
inhibit or stimulate the receptor.
There are two minimally necessary requirements for classification as a target; (1) it must be
druggable and (2) it must be linked to a disease. Drugability is the term coined for a target that can be
modulated by a ligand that has the appropriate bio-physico-chemical properties and bioavailability for
development into an effective drug27.
A recent study illustrated that of the 30,000 genes in the human genome, approximately 3,000
might be druggable and about 3,000 are disease modifying. However, the overlap of these properties is
expected to yield only between 600 and 1,500 targets.28 In fact, it is estimated that all drugs currently on
the market target less than 500 biomolecules29.
The typical large pharmaceutical company generally focuses on between 30 and 50 targets at a
time. As shown in Figure 8, target selection is considered from many angles, including business strategy,
research strategy and patient demand 30 . The Novartis Institutes for BioMedical Research takes the
following approach to target selection, which highlights the importance of understanding the mechanism
of a disease and therapy:
"We determine which diseases to focus our research efforts on based on two questions: Do we
have or can we gain significant understanding of the cause or "mechanism" underlying the
disease, and does this disease represent a significant unmet medical need in human well-being?" 31
27 Source: Bleicher, Konrad H. et al. "Hit and Lead Generation: Beyond High-throughput Screening." Nature
Reviews - Drug Discovery. 2, May 2003, 369-378.
28 Source: Hopkins, Andrew and Colin Groom. "The druggable genome." Nature Reviews --- Drug Discovery. 1,
September 2002, 727-730.
29 Source: Drews, J. "Drug discovery: A historical perspective." Science. 287, 2000, 1960 1964.
30 Much of the general information for this section is taken from Knowles, Jonathan and Gianni Gromo. "Target
Selection in Drug Discovery." Nature Reviews - Drug Discovery. 2, Jan 2003, 63-69.
31 Source: NIBR web site < http://nibr.novartis.com/OurScience/drug_discovery.shtml>
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Figure 7 - Drug Targets32
Figure 8 - Considerations for target selection33
3.3 Hit Finding and Optimization
A hit is defined as a compound that has been filtered for consideration in a biological assay by
showing significant and selective activity against a target and is believed by experts to show potential for
32 Source: Hopkins, Andrew and Colin Groom. "The druggable genome." Nature Reviews - Drug Discovery. 1,
September 2002, 727-730.
33 Knowles, Jonathan and Gianni Gromo. "Target Selection in Drug Discovery." Nature Reviews - Drug Discovery.
2, Jan 2003, 63-69.
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becoming a drug. Given an indicative biological assay, the principal method of finding and optimizing
hits utilizes high-throughput screening (HTS). An initial screen for hits, compounds that are found to be
active and selective beyond a predetermined threshold against the target, is generally run. Leads are
selected from the lists of hits and are further modified and retested until they exhibit the appropriate
behavior. Leads can also be inspired by natural products or result as the product of a molecular modeling
effort.
3.3.1 Bioavailability and ADME
Bioavailability is a term that describes the percentage of an administered dose of a drug that
reaches the target. To measure absolute bioavailability (F), one first plots blood plasma concentration
versus time for a dose of the drug taken both via the preferred method and intravenously, where
intravenous introduction is, by definition, perfect bioavailability. The ratio of the area under these curves
(AUC), scaled to the dosage size, is the absolute bioavailability of the drug administered by the tested
method.
F= AUC ,dose, 1
AUCIV dose
When considering drug potency it is important to consider the shape of the plasma concentration
versus time curve rather as well as the area of the curve. Typically, an effective drug will have a curve
that peaks fairly quickly, and has mostly dissipated within 24 hours. This allows a drug to be amenable to
a daily dosage regimen and reduces the potential for overdose.
ADME is the process of absorption, distribution, metabolism and excretion of a pharmaceutical
compound within the body.
Absorption is a measure of the uptake of the drug into the bloodstream and can be predicted by
several physical and chemical properties, including aqueous solubility, ionizability, and lipophilicity. In
vitro tools such as the CaCO-2 assay, which measures the drug permeation through cells that simulate the
gut wall, are also often used34. Often absorption is the rate limiting step for bioavailability.
Distribution is a measure of transfer through the bloodstream and into the tissue and organs.
Metabolism is the transformation of the drug compound, generally in the liver. Typically,
metabolites are produced by oxidation, hydrolysis and conjucation. The metabolites may or may not be
pharmacologically active. Though some limited success can be had predicting metabolism from chemical
34 Source: Guttendorf, Robert J. "The Emerging Role of A.D.M.E. in Optimizing Drug Discovery and Design."
<http://www.netsci.org/Science/Special/feature06.html>
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structure, most assessments of metabolism are made using in vivo experimentation such as tests using
liver redox enzymes, called cytochromes P450.35
Excretion is the removal of compounds from the body, generally in urine or feces. Incomplete
excretion can cause accumulation of foreign substances, which can hinder metabolism.
During the hit to lead process and further drug development, ADME, and consequently
bioavailability, must be optimized. First, sample libraries can be filtered using derivative rules of thumb,
such as the "Rule of 5" and "Rule of 3" described below.
3.3.2 Drug-like and Lead-like
The terms drug-like and lead-like describe critical attributes such as selectivity, activity and
ADME. Drug-like compounds resemble a potential final product, while lead-like compounds are
candidates for further optimization. It is generally agreed that optimization is a net additive process that
results in larger, more lipophilic compounds. Drugability is often estimated using the "Rule of 5"
championed by Christopher Lipinski, formerly of Pfizer Inc36. This set of guidelines received its name
from the observation that all of the criteria are set at multiples of five. The "Rule of 5" predicts poor
absorption and, consequently, poor oral availability. The "Rule of 3" is an extension of the "Rule of 5"
that is used as a guideline to filter non-lead-like compounds. It essentially provides a stricter filter to
allow for manipulation during lead optimization. The exclusion criteria for both sets of guidelines are
listed in Table 4.
clogP >5 >3
Number of Hydrogen bond donors > 5 > 3
Number of H dro en bond acceptors > 10 > 3
Molecular Weight > 500 > 300
Table 4 - "Rule of 5" and "Rule of 3" exclusion criteria
In the table above, "clogP" is the calculated value for the log of P, the partition coefficient. P is
the ratio of the concentration of the un-ionized compound in a non-polar organic phase, typically 1-
octanol, to the concentration in an (polar) aqueous phase. The logP is generally calculated because it is an
inexpensive, quick and relatively reliable way to obtain the value for a large number of compounds. If the
compound is highly ionizable than it is necessary to use D, the distribution coefficient, rather than P, for
35 Ibid.
36 Source: Lipinski, Christopher A., et Al. "Experimental and computational approaches to estimate solubility and
permeability in drug discover and development settings." Advanced Drug Delivery Reviews. 46, 2001, 3-26.
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evaluation. D is the ratio of the concentration of the compound in the organic phase, to that of a buffer
solution of the ionized and un-ionized drug. This test is dependent on the p1H of the buffer so it is not
easy to compare logD values across experimental teams that do not follow the same procedures.
1-Octanol is used in calculating logP because it resembles the lipids that form mammalian cell
membranes, which contain a polar head group and a non-polar tail. In the cell, the pair of non-polar tails
on the lipid are attracted to each other and to the pairs of non-polar tails on other molecules. Similarly,
the polar heads are also attracted to each other, creating a lipid bi-layer around the cell as illustrated
below. If the logP is too high, then the drug will not be soluble in an aqueous solution and will not be
able to pass through the lipid bi-layer in the gut. However, it should also be noted that if the logP is too
low, than the drug will not be lipid soluble and will be unable to pass through the bi-layer.
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Figure 9 - lipid bi-layer
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3.3.3 Combinatorial and Parallel Chemistry
Combinatorial chemistry is typically used as a high-throughput technique for producing a large
set of compounds for screening. The fundamental principal of combinatorial chemistry is the geometric
combination of various analogs of starting materials. If it is assumed that Material A has three analogs
and Material B has three analogs, then the combination of Material A and Material B will lead to nine
possible combinations.
Al + B1 4 Xl Al + B2 - X2 Al + B3 " X3
A2 + B1 4 X4 A2 + B2 - X5 A2 + B3 - X6
A3 + B1 - X4 A3 + B2 " X5 A3 + B3 - X6
Early combinatorial chemistry technique involved synthesizing and testing large mixtures of
unpurified compounds. However, this technique often led to false positive and negative results.
Additionally, upon discovery of a hit, researchers were faced with the troubling task of discerning the
active compound in the mixture. After purification these compounds were often found to have lost their
activity.37 The need to correct this shortcoming led to the advent of parallel chemistry, also know as high-
throughput chemistry (HTC).
A hit that has been uncovered through HTS, drug design, or some other method rarely has exactly
the desired properties for drug candidacy. Consequently, its properties are refined and optimized, often
using the techniques of parallel chemistry. Drug candidates can be simply described as comprised of a
backbone scaffold that supports one or more active functional groups, often called residues. Parallel
37 Source: Edwards, Paul J. "The Impact of Parallel Chemistry in Drug Discovery." IDrugs. 9, 2006, 347-353.
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chemistry is a general description of the techniques used to produce large numbers of backbone and
residue combinations. Parallel chemistry involves creating large numbers of structurally related, but
physically isolated, compounds. Often, Structure-Activity Relationships (SAR) and target knowledge of
the target are used for smarter design, resulting in smaller and smarter libraries as shown in Table 5.
Large Pharmaceutical 173 28,400
Medium-sized Pharmaceutical 104 4,100
Table 5 - Pharmaceutical Library Size38
3.3.4 High-throughput Screening
High-throughput screening (HTS) and ultra high-throughput screening (uHTS) are methods for in
vitro testing of large numbers of compounds in solution to find activity against and selectivity for a
specific target. Some assays also check for bio-availability and toxicity. HITS consists of highly
automated assays that typically perform simultaneous checks. Contemporary formats typically use 96,
384, and 1536 well plates.
The compounds for the initial hit-finding screen are generally taken from a large screening deck
of several hundred thousand compounds. Modem compound libraries, such as the Pfizer collection, can
contain up to five million compounds from both commercial and, preferably, proprietary sources. In the
early days of HTS, the goal of the administrators was generally to maximize the number and diversity of
compounds in the archive. However, this tended to provide a significant number of hits that were
doomed from the beginning because of one of a number of quality problems such as low purity or
insufficient uniqueness for intellectual property protection. General problems, such as molecular weight
drift, also tended to occur within the libraries, causing a general tendency for the compounds in the
libraries to lack oral availability, as predicted by the "Rule of 5".
When early HTS yielded sub-standard results, focus was changed to maximizing the drug-like
and lead-like features of the compounds in the library. Administrators of the libraries began instituting
specific rules for entry that barred compounds with specific types of functional groups, high molecular
weight, or other filtering criteria. Novartis, for example, requires all candidate compounds to pass a set of
38 Source: Kuhl, Philips L. "Best Practices in High-Throughput Chemistry." CH.A. Pathways. 4, 2004.
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three exclusion principals 39 . Internally synthesized compounds only need pass the first two, while
purchased compounds must pass all three. The principals are the following:
* Substructure filters for non-drug-like properties or other undesirable properties
* Compounds that are not stable in solution with DMSO or water
* Compounds with sub-structures that are abundant in the library or commercial catalogues
3.3.5 Rational Drug Design
As an alternative or supplement to high-throughput screening, leads can sometimes be developed
through statistical or mechanical inference. This is the case when the function and structure of a target
are understood in detail. This method generally uses computational chemistry and molecular modeling
along with biological, chemical and structural data to model small molecule interactions with targets in
silico, meaning with a computer. Computer Aided Drug Design (CADD) is used in many phases of drug
design. In target selection, CADD can help assess drugability, and modelers can help to understand and
interpret the detailed results from in vivo pharmacology. Most of these predictions are verified using
Quantitative Structure Activity Relationships (QSAR).40
QSAR makes the fundamental initial assumption that compound activity is a function of a
combination of physiochemical properties and structural properties. Hence, similar molecules will
display similar activities. QSAR predictions are generally made either by mining existing data to make
an prediction of behavior for an untested compound. A historical example of this technique was the
prediction of the boiling point for alkanes in the late 1800's based on the makeup of their carbon chains.
3.4 Pre-Clinical Testing and Drug Application
Eventually, if a viable compound has been produced, it will go through a multi-year series of pre-
clinical trials where the acute and long-term toxicity of a drug is tested. Formulation studies are initiated
and analytical and chemical development is started. In parallel, animal tested is initiated in rodents and
other species. One out of every fifty compounds that enter pre-clinical trials is successful 41. For the ones
that do, an investigational new drug (IND) application must be submitted to the FDA for approval before
clinical trials can begin.
39 Source: Schopfer, U. et al. "The Novartis Compound Archive - From Concept to Reality." Combinatorial
Chemistry & Hight Throughput Screening, 8, 2005, 513-519.
4C Source: "What do those modelers do?". <http://nibr.novartis.intra/news/2006/09-26_cadd.jsp>
41 Source: Pharmaceutical Research and Manufacturers of America. Pharmaceutical Industry Profile 2006.
Washington, DC: PhRMA, 2006, 47.
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3.5 Clinical Trials
Finally, the compound enters three phases of clinical trials. The overall time a compound spends
in clinical trials before becoming a drug is now an average of 8.6 years' 2 . Phase I trials are generally
performed on 20 to 100 healthy patients to verify the safety of the drug. Phase I I trials are performed on
about 100 to 500 patients that are afflicted with the target disease to examine effectiveness. Finally,
Phase III trials are performed on a large-scale set of 1000 to 5000 subjects and are used to check for
unwanted side effects and verify efficacy and dosage levels. Even after passing all the previous tests, one
half of all drugs that reach Phase III compounds eventually fail4 3 . Success in the trials leads to the quest
for FDA approval, after which the drug can be manufactured and sold.
3.6 Conclusion
It is generally recognized that the cost of drug development increases significantly with each step
in the drug development pipeline, as illustrated in Figure 11. Additionally, discovering a false lead early
eliminates the cumulative costs of all the successive stages of development. Consequently, it is extremely
valuable to drug developers to optimize the upstream processes to deliver the maximum number of drug
candidates while successfully filtering as many false leads as possible.
The following chapter discusses the approach taken in the research leading to this thesis, the
methodology used, and the metrics for success.
42 Ibid.
43 Ibid.
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4 Project Scope and Approach
4.1 Project Setting
The research for this thesis took place within the Chemical Libraries (CLI) team in the Lead
Synthesis and Chemogenetics (LSC) unit in Basel, as shown in Figure 12. One of the tasks of CLI is
Chemicals Management, specifically "to efficiently and cost-effectively provide researchers access to
commercial and proprietary chemicals in order to save time and resources." 5
The typical customers of Chemicals Management are within the Global Discovery Chemistry
platform, but also include scientists from other platforms and from the Disease Areas. Though local
chemists are the primary users of the chemical libraries, they are expected to be able to serve customers in
a variety of locations around the globe. Hence, compound management requires global utility that can
benefit a wide variety of physically dispersed customers.
NIBR ]
11 Disease Areas (DAs) Platforms Associated
Globaliscover Chemistry 6 Other P
Services
Worms
mputer Aided
Design (CADO)
:.ChemicalLi__brares,(CLl)
LedSntei
LO S fthe~sis &
Chemogenetics (LSC)'
l SC al:•
Hit Finding
Chemistry (HFC)
( igh ThroughputJ Chemistry (HTC)
LSC Cambridge
Chemicals
Management.
Figure 12 - NIBR Organizational Chart
4.2 Goals for Internship
The goal of this internship was to approach the Chemicals Management processes as an outsider
and to identify areas for potential improvement in the ordering, storage, and delivery of chemical
45 Source: Chemicals Management homepage <http://nibr.novartis.intra/GDIC/I SC/chcmmanage.jsp>
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compounds. The research took a two-pronged approach; the first goal was to look at current practices
from a near-term tactical viewpoint and the second was to look at the long-term strategic direction of the
group.
The short-term investigation looked at the current processes that were being used for acquisition
of new compounds for the archives, storage of these compounds, and delivery of the compounds to the
customer. The scope of the processes included, the customer ordering experience, the information
technology system used, the workflow in the archives, and the sharing of information of compound
between various archives and Novartis sites. The following major goals were specified:
* Determine the viability of automation of the storage and distribution of chemical reagents in
the archives
* Suggest the optimum location and quantity of archives on the Basel site
* Evaluate the operations of the archives and suggest short-term improvements as well as long-
term design improvements
* Determine the best point to make compound sourcing decisions
The long-term evaluation focused on creating an initial design for a compound archive as part of
the Novartis Campus Project. The Novartis Campus Project is a program to redesign the Novartis Basel
campus and create an academic university-style environment. As part of this project, the buildings that
are currently housing archives will no longer be available and the archives will be moved into a newly
constructed building.
4.3 Approach
The general approach taken in this project was to learn as much as possible about the system and
its current state, evaluate possible improvements to the system, critique the evaluations, and finally
discuss potential implementation. Because this research considered largely long-term changes, it was not
possible to become involved in implementation of changes, with the exception of improvement projects
that were currently underway at the outset.
The specific approach is as follows:
Step 1 was to have preliminary informal discussions with the operators and customers of the current
archives and labs, observe daily use and operation of the archives and associated software and engage in
an initial survey of associated literature.
Step 2 began with a medicinal chemistry course to further understand the day to day activities of chemists
and to gain further appreciation for the effects of materials properties on the processes involved in
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building block and intermediate delivery and storage. This was followed with further literature review, an
appraisal of the Information Technology (IT) systems that support the compound libraries, and a study of
automation systems that can be used for chemical storage and retrieval.
Step 3 included mapping the workflow in the Novartis Intermediates Archive and developing a system
dynamics model for evaluating benefits gained from improvement projects. This model was further
bolstered from data gained from a usage survey of customers.
Step 4 was an investigation into possible improvements by analyzing the process maps and visiting
competitor facilities.
Step 5 was to utilize the knowledge gained from the first four steps to produce a recommendation for the
design and operation of an archive as part of the Novartis Campus Project.
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5 Service Overview
5.1 Compound Management Options
There are several ways that a chemist can acquire chemical reagents and building blocks. The
most significant options that are internally managed by Novartis are the on-campus stockrooms.
Chemicals Management has defined the following three types of stockrooms:
Novartis Chemical Stockrooms (NCS) - These stockrooms store commercially available
compounds that are "overstock". They are searchable via the CIMS/SciQuest database tools.
Novartis Intermediates Archives (NIA) - These archives store reaction intermediates that are
not commercially available. They are searchable via the CIMS/SciQuest database tools.
Building Blocks Archives (BBA) - These archives contain a specially picked selection of both
commercially and non-commercially available reagents that are desired for their parallel synthesis
friendly properties.
In addition to the three types of archives listed above, chemists have several other sources to
select from for their reagents. Several groups have developed their own local archives that are accessible
only within those groups. Of course, labs keep small collections of frequently used compounds in local
stores. These compounds can also be shared with neighboring labs on an informal basis. Occasionally,
small amounts of some useful compounds can also be retrieved from the backup solid storage archive for
the Novartis Compound Archive (NCA), but this is a rare occurrence.
If a compound is commercially available, it can be ordered from a commercial supplier.
Commercial providers are divided into two tiers, labeled Preferred Vendors and non-Preferred Vendors.
Preferred vendors are generally more convenient sources because they offer a negotiated discount, have
more automated ordering processes, and maintain more up-to-date catalogues with Novartis. Non-
Preferred Vendors are generally found by searching the Elsevier MDL Available Chemicals Directory
(ACD) or by searching standard vendor catalogs. Though it recently switched from semi-annual to
quarterly updates, the ACD is still a lagging data source and often contains erroneous information.
Similarly, vendor catalogs are generally not updated frequently.
If none of the above resources provide the necessary compound and the chemist cannot determine
a suitable substitute, than s/he may need to synthesize it from precursors. This can be done within the lab
or by labs that specialize in compound synthesis as a service to other labs. Either way, this method is
costly in time and resources.
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It should be noted that these labels and the distinctions between them are somewhat fuzzy. The
legacy definition of a building block as synonymous with an intermediate is often used. In fact, what is
currently called the NIA was previously called the BBA. Also, the NIA has many compounds that belong
in the NCS under this taxonomy. When a compound is registered it is often a proprietary compound, but
becomes commercially available sometime after commercial registration. Figure 14 depicts the various
compound classifications and the overlap among them.
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5.2 Compound Search Methods
5.2.1 Local Archives
The two principal database search tools that are used to access chemical reagents are CIMS and
SciQuest. SciQuest is used in Cambridge and CIMS is used in the European locations. During this
internship, the European sites are in the midst of a transition from CIMS to SciQuest. Consequently, this
internship will focus on workflow utilizing the SciQuest system.
The introduction of SciQuest provides a number of significant possibilities for improving
compound management. The principal difference between SciQuest and the legacy CIMS system is that
the SciQuest database is indexed by bottle while the CIMS database is organized by compound. When a
bottle is checked out in the SciQuest system, ownership is transferred to the user so that others determine
where a compound is located. SciQuest also allows user to have her own local collections of compounds
tracked with the system and users can dispose of bottles that they have emptied.
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5.2.2 Commercial Compounds
If a compound cannot be procured from the local archives, then the lab begins a search of the
commercial vendors. Approximately 80% of commercially fulfilled compound orders are satisfied
through a select group of about ten preferred vendors. These vendors provide regularly updated catalogs
and negotiated pricing, saving the labs both time and money. For any compounds that are not available
from one of the regular commercial vendors, the labs must search through retail databases and catalogs.
This can be a very time consuming and frustrating process.
The online catalog that is used by NIBR is the Available Chemicals Database (ACD), provided
by Elsevier MDL. Users can search by structure, name, or CAS Registry Number. This database
provides quarterly updates, but the catalog is generally further out of date because many of the vendors
fail to update their inventory lists. Additionally, many vendors are in the habit of listing compounds as in
stock when they have not been synthesized. This leads to significant delays in delivery to the customer.
Several other indexes exist, including ChemCATS from CAS and ChemACX from
CambridgeSoft. ACD is generally regarded as the most thorough and complete database, but the author
considered the value of joining the databases to provide an even more thorough list. Unfortunately, there
is no common format for the databases and there are usage restrictions for somc. CAS, for example, only
allows interfaces to ChemCATS through their proprietary search applications, such as SciFinder.
Additionally, increasing the size of the database would not necessarily improve the quality of information
provided by the vendors. This can only be done through specific agreements with preferred vendors.
5.3 Customer Locations
Global Discovery Chemistry has approximately 770 lab heads and associates throughout the
world. This is a good general approximation of the population size and demographics of the Chemicals
Management group. Figure 15 illustrates the number of lab heads and associates by location.
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5.3.1 Basel, Switzerland
Because it is the oldest and largest location, Basel has the most thorough and complicated
compound storage facilities. NIBR has a presence in the St. Johann and Klybeck sites in Basel, which are
separated by the Rhine river. The Basel NIA is located in a building in Klybeck, the former Ciba-Geigy
site, along with a small NCS which is manned but allows self-serve usage. The larger NCS is located in
St. Johann, the former Sandoz site. There are also several small, restricted stockrooms located throughout
the campus.
Basel runs the CIMS system for compound search and ordering but is currently in the process of
upgrading to a SciQuest system.
Deliveries between the campuses are handled by a third party contractor. All compound orders
from vendors are also delivered to the contractor for check-in and then are distributed directly to the
proper lab or archive for use.
5.3.2 Cambridge, Massachusetts
The Cambridge site is designed from scratch and is not burdened with the legacy layout that
complicates compound acquisition in Basel. Hence, the intermediates archive and compound storeroom
share a common location that is easily accessible to all labs.
Cambridge was the pilot facility for the new SciQuest system and has been using it for a while.
A single archive acts as a storage location for all compounds in Cambridge. Unfortunately, this
archive is burdened by size constraints. Additionally, it is currently maintained by a contract service that
staffs the archive with employees that do not have knowledge of chemistry. Novartis has had difficulty
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keeping the lab staffed with personnel that have a chemistry background because there are not sufficient
career advancement opportunities.
5.3.3 Horsham, England
The Horsham facility has a central storage area that has been estimated to contain between 12,000
and 14,000 compounds but is not actively maintained. Compounds are initially checked in, but the record
is not updated after the initial receipt.
Horsham also uses the CIMS system, though there are no central archives to order compounds
from. CIMS is used for ordering commercial compounds and for ordering compounds for delivery from
Basel and Cambridge. The Horsham site is also in the process of an upgrade to the SciQuest system.
5.3.4 Vienna, Austria
There is no central storage in Vienna. All the compounds for each lab are handled by the lab
directly. Some informal sharing of compounds occurs between labs.
Currently, there is a manually maintained database of bottles contained at the site. However,
there is no barcode on the bottles to sort between them. Additionally, the database is considered
unreliable because it is not always updated as bottles are used and disposed. The Vienna site will also be
upgraded to the SciQuest system so that many of these deficiencies are addressed. It is estimated that
there are approximately 30,000 containers in the Vienna site.
5.4 Current Utilization
The pie chart in Figure 16 illustrates the origins of 759 orders from the NIA in Basel for the first
quarter of 2006. It is clear from this chart that the vast majority of orders from the Basel NIA come from
within the Basel community. This can be explained by a couple of factors. First, because the different
sites use different, unconnected IT systems, it is difficult for a scientist in Cambridge or Vienna to search
the compound archives in Basel. Second, shipping can be difficult. Samples larger than a gram are
subject to strict customs scrutiny in the United States and chemists often do not want to risk the potential
problems of shipping an unknown and unlabeled compound overseas.
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The Novartis Intermediates Archive in Basel delivered 2710 compounds, or 10.5 per workday, in
2005 as shown in Figure 17. 1952 of these orders, amounting to 7.5 per workday, required metered
dispensing in the archive and the other 758 were shipped as full bottles. Additionally, the NIA had 694
returns and 7934 new registrations, for a total of 8628 deposits, or 33.2 per workday, as shown in Figure
18. Compounds are rarely disposed unless the containers are leaking irreparably.
Basel Metered Basel Full Outside Metered Outside Full Total
Figure 17 - NIA compound withdrawals 2005
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Figure 18 - NIA compound registrations 2005
The Novartis Chemical Stockroom sent 8260 compounds, or 31.8 per workday, to its customers
in 2005. This is shown in Figure 19. It also received 7558 returns and registrations in 2005, averaging 29
per workday. Additionally, the NCS disposes of approximately 2000 compounds per year, or 7.7 per
workday. Currently, the NCS does not handle metered dispensing of custom weights.
2002 2003 2004
+ NCS 351
-NCS 136
-Linear (Total)
2005
Year
Figure 19 - NCS compound deposits
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Figure 20 - NCS compound withdrawals
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6 Evaluation of Improvement Opportunities
6.1 Determination of Value
The appropriate measure of value of any process and, consequently, any improvement project on
that process, is the benefit that the customer derives from the process that s/he would not have
experienced without the process. As discussed in the seminal book Lean Thinking46, this customer-
oriented view ensures that resources will not be wasted on activities that in no way enhance the end
product. It is very important to engage in discussion with the customer to avoid needless optimization of
qualities of a product or service based on the provider's often antiquated view of value, rather than the
actual measure of value from the consumer of the good or service.
In the case of the compounds management team, the customers are largely chemists. The reward
systems within Novartis for chemists vary by group but generally exhibit the same characteristics. They
reward primarily on the number of compounds delivered within a predetermined time frame and place
secondary emphasis on ensuring that some percentage of the synthesized compounds are used as
precursors for later stage compounds. This secondary metric is important because increasing the quality
of early drug candidates has a significant impact on cost and effort downstream, where the discovery
costs per compound are much larger. Consequently, any investments in compound management should
work toward the goal of improving the customer's ability to quickly synthesize structurally significant,
high quality compounds.
It is helpful to view this mission within a well defined operations strategy framework 47. The
potential objectives for any operations improvement can be categorized as improving (1) cost, (2) quality,
(3) delivery or (4) flexibility. Of course, cost improvements are always welcome, but it is important that
this does not infringe on the customer's ability to create high quality compounds. Hence, cost is
somewhat inconsequential, relative to the other three objectives. Quality is a significant parameter for the
customer because increasing the quality compounds in synthesis will have an effect on the number of
syntheses that fail due to low quality reactants, increasing the quantity of compounds that can be
synthesized. Reagent quality also helps determine the end quality of synthesized compounds, with regard
to bioavailability and intellectual property protection. Delivery time directly impacts the customer,
because a quicker turnaround time allows the chemist to begin synthesis more immediately. Finally,
46 Source: Womack, James P. and Daniel T. Jones. Lean Thinking. New York: Free Press, 2003, 29 - 36.
47 Source: Pyke, David. "A Note on Operations Strategy." The Amos Tuck School, Dartmouth College
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flexibility is of importance because increased flexibility increases the number of potential users and,
hence, the net benefit.
This chapter will discuss the results of an intensive investigation of the compound archives,
including the ordering processes, the archive operations, and the compound delivery and return processes.
First, the customer viewpoint will be discussed. Next, the compound ordering experience will be
considered, with special consideration paid to the optimum point for sourcing decisions. After this, the
workflow within the archive will be discussed. The next section will then discuss the contents of the
archives and rules to optimize the library. Finally, a brief competitor analysis will be provided to
compare the operations at Novartis to the state of the art elsewhere. The next chapter will provide a
special focus on archive automation.
6.2 User Interviews
After sketching the ways that value can be delivered to the customer, investigations were made to
quantify the value to determine the benefit of improvement projects. This was largely done with
customer interviews. However, because the chemists' time is highly valued, these interviews were kept to
a short and specific survey"' to quantify the general level of satisfaction and desire for improvement
followed with a few more detailed interviews to further understand how the customer used the service.
Customer interviews revealed that satisfaction with commercial compound delivery time was
fairly linear in the ten to two day range as shown in Figure 21. As expected, customers tend to care less
about incremental improvements outside this range. Exceptionally long delivery times have already had a
significant effect on workflow by ten days and other resources tend to be limiting at one day or less. The
results appear to be fairly similar for proprietary compounds, as illustrated in Figure 22, with the
exception that most interviewees showed a significant drop-off in satisfaction after two or three days.
This is because, with this level of delay, it now becomes attractive to synthesize the majority of
compounds or find a substitute compound.
48 The surveys conducted were short, multiple question surveys that assessed a user's satisfaction with quality with,
speed of delivery from, and ease of use of the various archives. They also asked several, optional short-answer
questions that inquired about potential improvements to or specific problems with the current system.
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Figure 21 - Customer satisfaction with delivery time for commercial compounds
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Figure 22 - Customer satisfaction with delivery time for proprietary intermediates
The general interviews show that customer satisfaction with the NIA and NCS is generally fairly
high. However, there remains room for improvement. To find some of these specific areas, more focused
interviews were conducted and several chemists walked the author through a typical ordering procedure.
In spite of corporate initiatives to place more compounds in general archives, the typical
inclination for chemists is to hoard compounds in local storage in their labs. Every chemist has the same
basic root desire to have the fastest access possible to the largest variety of compounds possible.
Unfortunately, depositing chemicals to the common archive presents a variety of prisoner's dilemma. If
all chemists register and deposit all of their compounds, the variety and delivery time will be optimized
overall. However, if an individual chemist deposits all of his compounds, and no one else does, s/he has
reduced access to his own compounds for no gain in variety or delivery time on compounds that s/he does
not own. Consequently, chemists tend to choose a local optimization over a larger, global optimization.
Several customers expressed confusion about the specific process for depositing compounds to
the archives. There is no specific process detailed for who is responsible for registering compounds and
what libraries they should be sent to. Others were hesitant to deposit chemicals if they were not certain
about the quality of the compound and did not have the time or money to test each individual compound
using analytical methods such as NMR.
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6.3 Compound Search and Ordering Evaluation
Figure 23, Figure 24, and Figure 25 below illustrate the compound ordering process from
preferred vendors, non-preferred vendors, and archives, respectively. The sourcing decision is made in
the lab using the process illustrated in Figure 26. The NIA, NCS and preferred vendors are searched
simultaneously using the new SciQuest implementation, but non-preferred vendors must be searched
separately, using ACD. Synthesis techniques are generally developed through literature review. The
order is then sent either to the vendor directly for preferred vendors, to the purchasing group in Research
Operations for the non-preferred vendors, or to the appropriate archive for processing. For non-preferred
vendors, Research Operations must negotiate a delivery time and price for the desired compounds and
communicate any irregularities to the lab. This can be a very time consuming and inefficient process.
Similarly, the archive staff must communicate any problems with an order directly with the chemist, who
will then make any new ordering decisions.
SciQuest Vendor
Novartis Vendor
Catalog
Figure 23 - Preferred vendor sourcing information and material flow
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Figure 24 - Non-preferred vendor sourcing information and material flow
tabase
I request
-----------------
SciQuest Compound unavailable Archive
Figure 25 - Archive sourcing material and information flow
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Figure 26 - Compound procurement decision tree
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This procedure has several inherent inefficiencies. Ordering decisions are made in isolation in
the labs, precluding any scheduling or price benefits that could be had by ordering the compounds in
aggregate from vendors. Also, learning effects that would result from one person handling all of the
orders, such as gaining familiarity with the more popular non-preferred vendors are lost. Additionally,
basic ordering tasks are often being performed by PhD level scientists, whose time is more appropriately
spent on drug discovery.
There is also a great deal of communication involved in the current ordering system when an
order is delayed, a compound is unavailable, or there are problems with pricing. For non-preferred
vendors, chemists or associates must negotiate with the vendor to secure the appropriate price and
delivery time.
A proposed solution for this problem is illustrated in Figure 27. This solution prescribes staffing
the Novartis archives with employees who have a chemistry background, but not necessarily a PhD, and
are tasked with sourcing all of the compounds for all labs. The lab would supply information about the
compound being ordered and the basics of its anticipated use. It would then be the responsibility of the
archive staff to determine the optimum source and quantity for compound. The archive staff would be
able to quickly remedy many of the pricing or delivery problems by immediately selecting a new source if
the initial vendor is unsatisfactory. For more ambiguous problems, the choice would return to the lab
with specifics of the problem and any alternative options, so that the lab can quickly make a decision. In
addition to providing a faster response time to problems, this frees up chemists to spend their time
discovering drugs rather than searching vendor databases.
There are a few potential drawbacks to this approach, however. The archives must be staffed
with employees that have a reasonable knowledge of chemistry. Consequently, archive staffers will
demand a higher salary. Also, steps must be taken to avoid gaming of the system by the labs. It would be
tempting for every lab to assign the highest priority to all of its compound requests so that it receives
undue attention from the archive. Since pricing negotiations and decisions will be made by the archive
staff that impact budgets for individual labs, the archive might be temped to simply order compounds
from the easiest vendor, rather than the best priced.
Most of these problems are easily remedied. The increase in salary for the archive staff will be
more than offset by the improved efficiency of the scientists that no longer have to spend their days
searching for compounds. To help inhibit scientists from gaming the system, rules could be implemented
that limit the number of rush orders before final approval is required from a unit head. Finally, the
archive performance metrics should be closely tied to the budgets of the individual labs and their year
over year savings on reagent spending.
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6.4 NIA Workflow Evaluation
The Novartis Intermediates Archive in Basel was selected for a workflow evaluation because it
will remain in service for several years in the future. The Novartis Compound Archive is in the process
of being moved to a new location, so time was not spent on process evaluation and improvement.
The principal goal of the workflow evaluation was to discover and eliminate muda in the process.
Muda is the Japanese word for waste and a key component of the Lean vernacular. Any action that does
not create, or even destroys, value as defined above, is muda. In Lean Thinking Womack and Jones
identify the eight types of muda, attributing the first seven to Taiichi Ohno, the legendary Toyota
executive, and adding the eighth themselves. The eight types of muda are as follows 4 9:
* Type I - overproduction ahead of demand
* Type 2 - waiting for the next processing step
* Type 3 - unnecessary transport of materials
* Type 4 - over-processing of parts due to poor tool and product design
* Type 5 - inventories more than the absolute minimum
* Type 6 - unnecessary movement by employees during the course of work
* Type 7- production of defective parts
* Type 8 - design of goods and services that do not meet the user's needs
The order fulfillment process was observed for several days to gain a hands-on understanding of
the exact steps that were actually implemented when filling orders. The information and material flows
were then documented in a current state process map, shown in Figure 29, which was constructed with the
help of the archive owner. Special attention was paid to the amount of time required for each step, the
time spent in transition between locations and any safety or quality problems. Several assumptions were
made in the representation of the process. While the size and daily composition of the orders is generally
extremely variable, it was assumed for this example that the order consisted of 16 specific requests, 8 to
be filled upstairs and 8 to be filled downstairs, that were divided amongst 5 customers. Half the samples
required metered distribution.
Currently, there is more than sufficient time available for order fulfillment and the process
bottleneck generally occurs in the delivery service. However, attention was paid to all steps because it is
anticipated that the required throughput rate will increase as the NIA becomes more popular. As the
49 Source: Womack, James P. and Daniel T. Jones. Lean Thinking. New York: Free Press, 2003, 351.
Page 55 of 87
delivery step is a batch process that has nearly infinite capacity, the bottleneck will eventually relocate to
another step. Additionally, reducing order fulfillment time will have positive effects on other processes
because the archive manager will have more time to work on compound registration and help with the
Klybeck NCS. At present, a second employee works part time to register compounds in the NIA. If order
fulfillment time can be reduced, than this is not needed.
The order fulfillment process begins when the archive operator checks his order database for
unprocessed requests using the CIMS system5o. This typically happens first thing in the morning when
the operator begins his day. He then prints a set of labels, one for each order, and sorts them based on
physical location of the source bottles, which is listed on the label, and whether the requests involve
metering. He then proceeds to the storage rack and retrieves the compounds that are located in the
upstairs storage, generally in order of location from furthest from scale to closest. Next, he travels to the
scale, under a fume hood, and weighs out specific amounts of the compounds to be metered. This step
requires him to select a destination bottle by eye. Occasionally, he chooses the incorrect bottle and is
required to select a new bottle and restart the weighing process.
After he completes the upstairs orders, the archive manager travels downstairs and performs a
similar operation with the compounds located in the basement. After he has selected and weighed all of
the requested compounds, he then carries them back upstairs, by hand or on a cart, via the elevator. Once
upstairs, he batches the two sets of orders together by location. Orders that are deliverable to local
Klybeck labs are dropped off by the archive manager. If the lab is empty, he is forced to return later for a
second visit. Orders that go to the St. Johann campus are put in plastic buckets with packing peanuts and
the labels are taped to the outside. All the orders that are shipped outside Basel are placed together in a
container to be sent to Johnson Controls central receiving for processing, packaging, delivery. All
containers that are not dropped off by hand are placed on a specially labeled shelf on the building loading
dock for pick up by Johnston Controls to be taken to the correct lab or to central receiving. Johnson
controls generally comes twice per day, once in the early morning and once in the late afternoon.
The total process in this example from acknowledgement of the compound request until the
requests are successfully hand-delivered or placed on the loading dock for pickup is approximately 72
minutes, but this time is extremely variable and difficult to predict. The size and composition of the
compound request list varies largely from day to day. The number of requests that require metering
drastically increases the processing time, as do any locally requested compounds that require more than
one attempt for hand delivery. The amount of time between placing an order and receiving a compound
50 The CIMS system is currently in the process of an upgrade to the newer SciQuest system, but the fulfillment
process will largely remain the same.
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for a chemist varies by site. Chemists on the Klybeck sight generally receive their compounds within 24
hours, chemists in St. Johann wait between 24 and 48 hours, and chemists outside Basel wait up to a
week, or longer if the compounds are held in customs.
The following problems were noted with the NIA order fulfillment process:
* Muda Type 4 or Type 7 - Container picking was done manually with no verification that the
correct bottle was selected, leading to possible time loss due to picking the incorrect bottle.
* Safety consideration - All containers were stored in a somewhat open air environment,
especially in the basement storage area, exposing the archive administrator unnecessarily to
compound fumes. This is illustrated in Figure 28.
* Muda Type 4 - Selection of compound vials was done by eye, generally with the goal of
locating the smallest vial that would fit the requested quantity of the compound. This often
resulted in replacing the bottle with a more appropriate size.
* Safety consideration and muda Type 7 - Compounds were often carried by hand, creating
potential for dropped compound bottles
* Safety consideration - Compounds were carried on the standard elevator.
* Muda Type 6 - Compounds in the basement and on the main floor are located a good distance
from each other, causing a significant amount of wasted time moving between the two
locations.
* Muda Type 2 - Johnson Controls pickup service was an obvious bottleneck in the process,
and pickup times were inconveniently timed. The early pickup time is often before the
archive can prepare compounds for delivery and the later pickup time results in compounds
arriving too late for the lab to begin using them.
* Order processing time is highly variable due to uncertainty of quantity of metered
compounds, uncertainty about success of hand delivery and general variations in lab work.
* Muda Type 7 - Packing peanuts in plastic buckets often caused compound vials to be lost.
Occasionally, a lab will receive an order that has an extra vial that had fallen to the bottom
and was missed in the previous unpacking.
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Figure 28 - Current open air archive
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A few of these problems are not easily remedied. The compound storage units are fixed and
cannot be relocated without making structural changes to the building. Also, installing a special elevator
for chemicals is not possible without a major structural overhaul to the building, nor is changing the
compound storage system to a sealed, ventilated storage unit. However, it is important to note these
problems for consideration with future archive designs.
The following proposals are designed to eliminate some of these problems and inefficiencies with
the current process. An improved future state map is shown below. The numbered clouds indicate
changes.
* Compounds can be checked out of the software database with a handheld barcode reader as
they are removed from the storage racks. This provides an auxiliary verification that the
archive manager removed the correct bottle while eliminating the possibility that a bottle is
removed from storage and not checked out of the software database. (cloud 1)
* The current storage is ventilated as well as possible, but future installations should use closed,
well ventilated storage systems.
* Compounds should, as a rule, be placed into a vial that is considerably larger than the
expected required size. The cost difference between the vials will be more than overcome by
the savings in fulfillment time by reduced errors.
* A cart can be made available for carrying compounds at all times. This cart should have a
specially designed grid on the top shelf for holding various sized bottles so that they do not
slide when the cart is moved.
* Rearrange delivery from Johnson Controls so that the pick up containers before lunch and at
the end of the day. These pickup times would significantly reduce the amount of time that
compounds wait on the loading dock. If process time is reduced sufficiently so that the
archive manager can complete three cycles per day, then three pickups should be arranged
near the time of completion of each of the three cycles.
* Metering of compounds can be eliminated. The new SciQuest system is able to track
compounds in labs, so that they can be located when in use. Consequently, a chemist can
withdraw the whole bottle, use the quantity that s/he requires, and return the bottle when
finished. Other chemists will be able to locate the bottle if necessary51 . (cloud 3)
51 A potential exception to this rule should be made for especially valuable compounds which are rationed. Also,
metering is likely an appropriate solution for the future Building Block Archive
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* Rather than delivering compounds by hand, the archive manager should place local orders in
a general pickup depot and send an E-mail to the chemist stating that the compound is ready
for pickup. This way, the chemist can arrange to acquire the compound when it is convenient
for him and no time is wasted with attempts to deliver to an empty lab.
* Install foam padding in the buckets rather than packing peanuts. The foam padding can be
used to protect the vials without allowing them to fall to the bottom of the bucket and become
lost.
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Figure 31 is a travel map of the order fulfillment process. This map helps to illustrate any muda
Type 6 and Type 3 that are inherent in the process. It is clearly obvious that locating the parts of the
archive closely to each other would significantly reduce travel. Additionally, the layout should be
changed to allow the operator to move in a circular fashion around the room, beginning at the computer
workstation, traveling to the storage cabinets, and proceeding to the scales and packing desk.
Unfortunately, the chemical storage cabinets are fixed so that their position cannot be altered, but this is
important to note for future designs.
Figure 31 - Travel map of order fulfillment in NIA
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6.5 Archive Content Evaluation
Customer demand should drive the functionality and content of the archives so that they are able
to store and deliver exclusively compounds that will prove valuable to the customer, as measured by the
four operational metrics discussed at the beginning of the chapter. Consequently, it is valuable to audit
the current contents of the archives and reflect on how future operations can optimize the inventory and
eliminate muda Type 8 and Type 5, described in the previous section.
As described above, the customer for the compound libraries is generally interested in producing
lead-like and drug-like compounds as described by the "Rule of 3" and the "Rule of 5", respectively.
Figure 32 plots the molecular weight profiles of the Novartis Intermediates Archive and the Novartis
Compound Stockroom in Basel. The pink line represents the profile for a lead-like library that is
governed by the "Rule of 3". The purple line depicts the molecular weight profile for drugs listed in the
Physicians' Desk Reference, which acts a proxy for a drug-like library.
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Figure 32 - Molecular weight profiles for archives in Basel
From this chart, it is apparent that the Novartis Intermediates Archive has experienced what is
known as molecular weight creep. When chemists manipulate the properties of a candidate compound,
they tend to favor additive processes that result in a final material with a greater molecular weight than
the starting compound. Over time, as the newly synthesized compounds are added to the archive, the
average molecular weight of the entire archive tends to drift higher. This is a problem for drug discovery
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because higher molecular weight compounds are shown to have poor oral bioavailability. When viewed
within the framework discussed earlier, this observation exposes potential opportunities for improvement
in quality of compounds available, with secondary effects on cost of maintaining the archive and delivery
time.
This problem can be partly remedied by instituting a rule requiring compounds over a specified
molecular weight, likely close to 500, to be entered into the archive only after special consideration.
Below this limit, filtering by molecular weight will have to be done at the discretion of the chemist,
perhaps with help of an educated archive staff.
Compound quality could also be improved by instituting other filtering rules for depositing a
compound into the NIA. The rules that are currently in place include the requirement that a compound is
novel, of a sufficient quantity to be useful to the archive, and that the compound does not provide any
intractable safety hazards. Additionally, rules can be added per the "Rule of 5" discussed earlier to ensure
that the NIA provides a high density of useful synthesis intermediates.
The compound accumulation profile shown in Figure 33 below illustrates the growth pattern for
the compound libraries and can be used to extrapolate future changes in population size. The population
of the Novartis Compound Stockrooms has remained relatively stable, indicating that compound
withdrawal or disposal and submission are at equilibrium. The NIA, on the other hand, appears to be
growing at a steady rate. This is largely due to metered dispensing. Because compounds in the NIA are
proprietary, novel substances, users are asked to only request the amount that will be used. Consequently,
the number of bar-coded bottles in the compound generally increases with time. This linear growth must
be noted when planning storage capacity for the NIA and has a significant on the archive operational cost
with a secondary effect on delivery time.
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Figure 33 - Compound accumulation profiles for archives in Basel
A significant subset of the compounds that are in the NIA is not actually novel, proprietary
compounds. This has occurred partly because some of the contents in the NIA are remnants of a legacy
storage system, but also because, over time, many of the more useful proprietary substances eventually
make it into general circulation and should be reclassified as commercial compounds. Of course, it is not
practical to make regular checks of the entire archive contents for such compounds. A better solution is
to merge, either physically or by utilizing a mutual database, the NIA and NCS. This would eliminate the
creation of an overabundance of some compounds through the creation of redundant supplies in both
archives.
6.6 Competitor Analysis
Competitor analysis is somewhat difficult to perform because many pharmaceutical firms hold
their drug discovery processes as a closely guarded secret. However, the author was able to gain some
insight by interviewing with Novartis employees that had previously worked for competitors and from
touring a Hoffmann LaRoche facility.
For many pharmaceutical manufacturers, combinatorial chemistry is not considered a core skill.
Consequently, there is a significant trend in the industry to outsource some aspects of combinatorial
chemistry to specialist third parties. Most pharmaceuticals, however, continue to maintain a large
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proprietary library of compounds onsite, as this is considered central to their intellectual property
strategies. This arrangement would place less emphasis on the maintenance of archives, such as the NIA
and NCS, which would be part of the scope of outsourcing. Other manufacturers, including Novartis,
wish to maintain a large combinatorial chemistry group, but are interested in supplementing part of their
work in collaboration with third parties.
A tour of the Roche chemicals storeroom presented an interesting point of comparison to the
facilities at Novartis. The Roche storeroom uses a CIMS database similar to the one at Novartis to keep
track of compounds. However, it uses a Kardex system with automated pick and place to store and
retrieve the compounds. This system offers faster compound retrieval and depositing than the manual
system at the NIA, requires barcode verification of retrieved compounds to check for errors in selection,
and provides a climate controlled, isolated storage for the compounds. This significantly reduces travel in
compound acquisition while providing a safer, cleaner environment for the archive staff.
The scope of the Roche storeroom is also somewhat different from that at Novartis. First, the
storeroom acts as a central receiving for all compounds for all labs. Consequently, it can keep track of the
number chemical entities that each lab has and restrict ordering until the lab has returned compounds if
they have accumulated too many. Second, it handles the ordering of all compound substances,
aggregating decisions and freeing chemists to perform higher value-added tasks, as described above.
Third, it is responsible for all chemicals, including high volume, commodity orders. This allows for a
smaller overall stock of compounds on hand because there is a reserve that is aggregated for all labs rather
than a separate reserve for each lab, reducing muda Type 5. Additionally, it requires less effort to
replenish a single inventory than to replenish many smaller inventories, decreasing muda Type 6. Finally,
the workflow is designed to reduce travel, further reducing muda Type 6 and also decreasing Type 3. The
archive manager works in a circle, starting with receipt of the orders and finishing by dropping off the
orders at an adjacent pickup station.
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7 Stockroom Automation
7.1 Overview
Stockroom automation was considered as a potential source for improving quality and delivery.
The two separate types of automation that were considered for a stockroom were storage and retrieval of
compounds and weighing of dispensed compounds. Currently, manual dispensing procedures are
implemented in the NIA and are planned for the BBA, while the NCS only distributes whole bottles. It
has already been decided that pick and place automation will be utilized in the new instance of the NCS.
Consequently, this chapter investigates only implementation of dispensing automation.
7.2 Current Implementation Examples
Automated compound handling is commonly implemented for high-throughput screening
archives, such as the Novartis Compound Archive (NCA). The NCA consists of three automated
sections, shown in Figure 34. The Automated Compound Archive utilizes a pick and place algorithm to
command a robot to retrieve and restock powdered compounds in uniform storage vials. This archive has
a capacity of approximately I million compounds in 1 - 500 mg quantities and saw more than 9000 new
submissions in 20055.
52 Source: Novartis SOLAR poster presentation
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The Automated Solution Production is an automated process for weighing precise quantities of
powered compounds and creating water/DMSO solutions in 96 well blocks from powdered compounds
and placing these solutions in storage. A single scale typically performs 100,000 weighing operations per
year and the entire archive produces approximately 300,000 new solutions per year. This high volume is
partly due to the strict policy of replacing solutions after three years to ensure purity.
Finally the Automated Solutions Archive (SOLAR) is capable of cherry-picking individual
solutions and pipetting them into 96, 384 and 1536-well trays for testing. The goal of this process is to be
able to produce error-free samples in the smallest quantity available. At the time of this writing, plans
were being made to replace the pipetting system with an ultrasonic system that allows even smaller, ultra-
high precision samples to be dispensed. A specifically tuned longitudinal is used to propel the solution
from the source vial to the desired well.
7.3 Initial Assessment
The dispensing process in the chemical storerooms is comparable to the Automated Solution
Production process in the NCA while the pick and place process is similar to the Automated Compound
Archive. Table 6 is a quantitative comparison of the NCA with the chemicals stockrooms in several of
the properties that are important when considering automation. This table illustrates that the throughput
and size of the chemicals storerooms are considerably smaller than the NCA. Additionally, the
53 Source: Schopfer, et al. "The Novartis compound Archive - From Concempt to Reality." Combi Chem and High
Throughput Scr, 8, 2005, 513-519.
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uniformity and precision of deposit and withdrawal activities is much less important for these archives
than for the NCA. The Law of Requisite Variety, which essentially states that the complexity of a
controller must be greater than or equal to the complexity of the system being controlled, suggests that
higher variability in the shape and size of the container and the quantity being deposited and withdrawn
will require a more complex automation and control system. Also, because there is significantly less
throughput, the costs of the system are spread over a smaller set of operations, meaning that the benefits
per operation required to justify those costs must be greater.
I - u mg
300,000 / year
. Few mgs
Very High
I million compounds
Very uniform
I g - several Kg
3000 / year
-50mg - kgs
Low
30,000 compounds
Variable
Ug - lKg
7000 / year
Entire Quantity
Low
10,000 compounds
Variable
Table 6 - Comparison of NCA, NIA and NCS
7.4 Available Automation
7.4.1 Dispensing
Dispensing solutions were available from several vendors that have a working relationship with
Novartis, including Mettler-Toledo, REMP and Autodose. The REMP solutions were designed for use
almost exclusively with assay trays and were eliminated from consideration. The solutions from the
remaining two vendors are detailed in Table 7.
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ueposl v olume
Withdrawal Frequency
Withdrawal Volume
Withdrawal Precision
Archive Size
Container Uniformity
System Name Powdernium Flexiweight 1000
Range of Physical High 85% of typical library
Properties
Throughput Time 20 to 40 s Best 20 s
Mean 70 s
Weight Range 0.05 mg to several g 1-20 mg FlexiCap II
Img -_I g FlexiCap III
Precision +1 - 5% ±0.2 mg FlexiCap II
±0.3 mg FlexiCap III
Target Container Almost all Any vial up to 15 cm
diameter
Source Container Almost any small Up to 16 ml
Table 7 - Automation Solutions
The automation systems that are currently on the market are not ideally configured for application
to the archives. The weight ranges for both systems listed above are considerably below the ranges of
typical dispensing for the NIA. In 2005, only 1,002 of 1,952 requests were for weights of less than one
gram. Additionally, they are configured for a small number of source containers rather than the tens of
thousands that are currently available for dispensing from the NIA.
A quote was obtained from Mettler-Toledo for the Flexiweight solution. A basic configuration
was priced at CHF 240,349 (USD 192,500). A back of the envelope calculation demonstrates the
infeasibility of economic justification for this purchase. If it is generously assumed that this system is
used to dispense 1,000 compounds per year for a ten year life, the cost per compound dispensed is CHF
24.03 (USD 19.25). Of course, it is unlikely that the system will receive 1,000 orders per year, since it
will only be able to dispense a select subset of compounds in the NIA. Additionally, installation costs,
and recurring costs, such as dispensing caps, have not been included in this calculation.
The anticipated Building Block Archive, on the other hand, might be an excellent use of
dispensing automation. If it is assumed that this library only stores approximately 1000 compounds that
are specially picked to be amiable to dispensing and for high-volume, common use, then the current
technology is well suited for this application. It is generally expected that the BBA will handle
approximately 75 requests per day. Again, using the same approximate calculation as above, the capitol
costs are now CHF 1.33 (USD 1.07) per vial.
54 Source: Autodose homepage <http://www.autodose.ch/dispensing-capabilities.html>
55 Source: Conversation with Mettler-Toledo representative and homepage
<http://us.mt.com/mt/products/products/FlexiWeigh 000_Product-Product I 108485387750.jsp>
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7.4.2 Pick and Place
At the time of this investigation, a pick and place system from Kardex AG was already evaluated
and selected for implementation in the new NCS installation. Consequently, a financial evaluation of
options or viability will not be performed. The previous discussion and Table 6 initially raise concern
about justification because there are two orders of magnitude fewer withdrawals from the NCS than from
the NCA. Additionally, implementation might appear challenging because the size and volume of the
library contents vary considerably more for the NCS. However, pick and place automation differs from
small-volume, high-variety compound dispensing automation in that it is a common source of automation
among many different industries that often require storage of lower-volume, non-uniform inventories.
7.5 Conclusion
While pick and place solutions exist that are appropriate and justifiable for the NCS and NIA,
there is currently no viable dispensing solution. However, pick and place should remain in consideration
for the BBA. The costs of implementing the currently available automated dispensing systems are
significantly greater than the in-place process. Additionally, the material property flexibility and source
compound variety do not yet exist for the large variety of compounds that are used in these archives.
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8 Vision for the Future
8.1 Objectives
The Novartis Campus Project is an ambitious undertaking that aims to transform the Basel St.
Johann site "from an industrial complex to a place of innovation, knowledge and encounter." 56 Over the
next several years, many of the current buildings on the campus will be raised and replaced with newly
designed offices and labs that aim to provide a more collegiate environment.
The Campus Project is an excellent opportunity to redesign the NIA and NCA from the ground
up, and to implement the lean principals discussed in this thesis. Because the new archive will not be
built for several years, the following discussion is intended as a general guideline for future planning.
8.2 Archive Fundamentals
The NIA, NCA, and BBA will be combined into a single archive in order to eliminate the
redundant inventories that contribute to muda Type 5 and to help level the highly variable throughput
through each library. A potential layout for the archive is illustrated in Figure 35. The travel path for
compound order fulfillment is a circle around the archive, beginning with order receipt at the workstation
to the left of the entrance, traveling to the Kardex system for compound acquisition, proceeding to the
fume hood for required metering, continuing to the packaging table to prepare compounds for shipping,
proceeding to the outgoing depot to drop off completed orders, and finishing back at the Kardex to return
the source vials. This path is designed to minimize operator and compound travel, muda Type 3 and Type
6, respectively. To minimize the risk of dropped compounds, a cart to hold the compound vials will
travel with the archive staff member throughout the entire fulfillment process.
The global stockroom will handle all of the commercial and proprietary requests. Projections for
future usage were made from the currently available data, discussed above. It is also assumed that
approximately 75 daily withdrawals will be made from the 1000 available building blocks. The
projections are summarized in Table 8, below. The storeroom is designed to hold 150,000 compounds.
This value was derived from extrapolating Figure 33 eight years into the future.
56 Source: <http://www.novartis.com/about-novartis/locations/basel-campus-project.shtml>
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Metered Withdrawals 83
Non-metered Withdrawals 34
Returns and Registrations 62
Disposals 10
Table 8 - Projected throughput for Novartis Campus Project archive
Metered dispensing will be included for a select group of approximately 1000 Building Blocks
and, if desired, for chemical intermediates. Currently automation is not recommended for dispensing of
intermediates, but should be considered for building blocks.
The compound storage system that was selected for this scenario is the ShuttleXP system by
Kardex AG. This system consists of a series of enclosed shelves that are used to hold the compounds.
Vials are picked and placed by an automated extractor that is able to move vertically and horizontally
simultaneously. Compounds are generally placed in locations to minimize total travel for the extractor,
but specific areas can be specified for volatile compounds or compounds that might react with their
neighbors. Cold storage is also available. For more specific specifications of the suggested Kardex
system, refer to the Appendix.
The Kardex system provides several benefits to the chemical storeroom. First, it significantly
reduces the physical footprint of the storage unit compared to non-automated systems. It also contributes
to reductions in muda Type 3 and Type 6. The barcode scanner that is attached to the access opening
reduces errors caused by selecting the incorrect bottle because it will indicate an error if the incorrect
bottle is selected. Finally, it is more airtight than a manually accessed shelf system, reducing the archive
operator's exposure to compound fumes.
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8.3 Project NPV Analysis
Table 9 below is the result of a preliminary NPV analysis for the new archive. These calculations
assume that the entire project is financed with cash upfront, that the new building will be constructed
regardless of the decision to produce a new archive, and that the opportunity cost of occupying the new
location is exactly balanced by the opportunity benefit of vacating the old location. Only the very large
capital expenses have been included because the uncertainty in predicting costs this far into the future is
greater than most of the smaller expenditures. The expected lifetime for the archive is projected at 20
years. The cost for the Kardex system and scales were extrapolated from quotes received for similar
orders. The savings in commercial compound expenditures are calculated on the assumption that the new
archive will be sufficiently attractive to reduce overall compound ordering by 1%. Under these
conditions, the break-even point for NPV is a 0.111% decrease in overall compound ordering. If it is
assumed that there are no reductions in staff (FTE 57), then the break-even point is a 0.377% decrease in
ordering.
Category Description NPV
Capital Kardex ($687,000)
Scales ($24,000)
Installation Kardex ($140,533)
Operation Commercial Comp Savings $2,256,000
FTE Required ($3,000,000)
Old System $3,600,000
Net $600,000
Total Total $2,004,467
Table 9 - NPV estimate for new compound archive
57 FTE is a Full Time Equivalent, equal to the resources consumed or produced by one full-time employee.
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There are several other benefits from this project that are not easily quantified. The following list
details several of these improvements.
* Safety is improved in the archive due to better fume containment and removal in the Kardex
system.
* Ordering errors are reduced because of increased automation.
* Service level and reliability increase as a result of the leveling effect of demand aggregation.
* Compound inventory is reduced because of elimination of redundant stocks.
* Compound ordering is faster for the chemist because the compound archive handles most of
the ordering activities. Additionally, overall compound ordering time is reduced because
there are fewer databases to search.
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9 Conclusions
Procedures for using compound archives and libraries must be clearly presented to the end
user.
Surveys and interviews with users indicate that chemists are often confused about the exact
procedures for depositing to the compound libraries. It is important that a clear and global procedure is
identified and clearly stated that defines the quantity of compound that is to be sent to the library, the
libraries that should receive the compound, including the Novartis Compound Archive, and the testing
that is expected before deposit. Additionally, clear rules should be established for determining whether a
compound should be deposited to a library and which libraries it should be deposited to.
Compound libraries should be conglomerated into one large library that is also responsible
for all compound acquisition.
The various Novartis Chemical Stockrooms and Novartis Intermediates Archives should be
combined into a larger central archive. This will have several primary benefits. First, because the
definition between an intermediate and a compound which belongs in the NCS is blurred and often
changing, there is a large set of redundant compounds between the libraries. Elimination of this
redundancy will significantly reduce the quantity of compound that is required on hand and will increase
delivery and compound quality. Second, orders frequency from the stockrooms is highly variable and
fluctuates erratically. Combining several highly variable demands into one larger demand pool will
reduce this variability and result in better utilization of archive staff and facilities. Finally, combination
of the archives sets the stage for moving all compound ordering responsibilities to the central archive.
This would free chemists to spend their time on chemistry rather than compound ordering.
Compound metering for intermediates does not appear to be an effective use of resources.
The current method of delivering metered samples of compound intermediates to chemists may
no longer be of value under the new SciQuest compound management system. The value in this process
is considered to be two fold. First, it is said to save material because the chemist only receives the exact
quantity that s/he requires. Second, it allows the compound to remain in a centralized location where it
remains available to other users. However, because of the tendency for chemists to be conservative, a
fixed, one-shot order system often encourages them to order more compound than they might actually
require. Additionally, the metering process does not save any time for the chemist because s/he will have
to reweigh and distribute the compound during the synthesis process. Because of the new SciQuest
ordering system, all compounds will be searchable in all locations, including the labs, so other chemists
will be able to locate and request a compound, even while it is in use.
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Library automation currently makes sense for pick and place but not for compound
metering and dispensing.
The current state of the art in available automation systems dictates that storage and retrieval of
compounds should be automated, but that metering and dispensing should be done manually. Modem
storage systems, such as the Kardex system reviewed above, allow for safe, clean storage with a
considerably smaller footprint as well as error-free and fast depositing and retrieval. However, current
metering systems are not yet up to the task of handling the high number of compounds and high variety of
physical properties that are stored in the libraries.
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11 Appendix A - Glossary of Drug Discovery Termss8
Assay
Bioavailability59
Combinatorial
chemistry
Drugability
High-throughput
screening (HTS)
Hit
In silico
In vitro
In vivo
Lead
Lead finding
Lead optimization
A biological test, measurement or analysis to determine whether compounds have
the desired effect either in a living organism, outside an organism, or in an
artificial environment.
The percentage of a drug's active ingredient that reaches a patient's bloodstream
and body tissues.
Set of techniques for synthesis of a large number of compounds, including parallel
chemistry and production of mixtures in both solid phase and solution
The term coined for a target that can be modulated by a small molecule ligand that
has the appropriate bio-physico-chemical properties and bioavailability
Approach to detect inhibitors, stimulators or modulators of a specific biological
interaction by testing large amounts of chemical entities mostly with the help of
automated systems.
Library component whose activity exceeds a predefined, statistically relevant
threshold.
Describes an experiment that is done with a computer.
Describes an experiment that is done in a test tube.
Describes an experiment that is done in an animal or human body.
Chemical entity with biological activity for chemical optimization to improve
potency & specificity. Selected as a starting point for drug development.
A process where early lead compounds can be identified from the existing
compound libraries, normally by high-throughput screening using in vitro and/or in
silico approaches.
A process where the designed activity/efficacy/drugability can be
improved/optimized by modifying the chemical structure of known scaffolds or
switching to a new templates (or changing chemical space).
Lipid
58 Some terms are not uniformly defined throughout the industry. Where there is inconsistency this glossary is
reflective of the Novartis definition. Other definitions come from http://www.combichemistry.com/medical-
chemistry-glossary.html
59 Source: Saftlas, Herman., ct. Al. "Hlealthcare: Pharmaceuticals." Standard & Poor's Industry Surveys. May 25,
2006.
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New Drug
Application (NDA)
Parallel chemistry
Pharmacokinetics60
Rule of 5
Scaffold
Selectivity
Singleton
Target
A document submitted to the FDA requesting permission to market a drug.
A specific method of combinatorial chemistry by which large numbers of single
compounds are synthesized in parallel.
Analysis of a drug's absorption and distribution in the body, its chemical changes
in the body, and how it is stored and eliminated from the body.
A set of rules used to filter compounds for drug-likeness developed by Lipinski,
formerly of Pfizer.
A structural backbone
A term used to distinguish between the desired activity of a drug and its other
effects.
A colloquial term for an active compound that lacks active neighbors in structural
space.
Biological molecule (gene, protein, bio-chemical) that is believed to be linked to a
given disease. Modulation of target activity or levels by certain biologically active
compounds represents therapeutic opportunities.
60 Ibid.
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12 Appendix B - CIMS and SciQuest Screenshots
I..lnP·~8a~-~~~5:~~:~
Rule of 5: (for more information see ChemPK home page)
Number of violations = 0
clogP = 3,568
Molar refraction :7 :::
MolWeight = 147.0
H-bond acceptors =O
H-bond donors0:
PSA 0,0
Amide bonds = 0
Paste results?
w::::ir :
: : :r :.:: . :i  .:..:. . :.... :ii .; ... .....  .i.!•:/ .. :.
Figure 36 - CIMS "Rule of 5" screenshot
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Figure 38 - SciQuest search interface
Page 86 of 87
iQ(1,-,I t It ýrpiw hr Oeýktc
. ...............
.... ... ..............
.~~~--~-~111~111-~-1II
:;i
13 Appendix C - Proposed Kardex Configuration
The proposed Kardex implementation for the Novartis Campus Project assumed a storage
capacity of 150,000 compounds with a composition described in Table 10. The model contains three
access openings, that are 3,237mm x 813mm x 1850mm. The required volume without the openings is
detailed in Table 11. When the volume required for the openings is added, the ShuttleXP system requires
approximately 23 standard units"' or 12 double-height units.
Table 10 - Projected archive composition
:small
Medium
Large
Extra-Large
Total
161
90
81
35
367
100
125
150
300
16100
11250
12150
10500
53237
24215
16920
18274
15792
74202
Table 11 - Projected archive storage requirements
6' A standard storage unit has 2371 mm of useful height and a shelf surface of 813mm x 1850mm.
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